A phase I study of talazoparib ( <scp>BMN</scp> 673) combined with carboplatin and paclitaxel in patients with advanced solid tumors ( <scp>NCI9782</scp> )-Reference-Cited by-同舟云学术

A phase I study of talazoparib ( BMN 673) combined with carboplatin and paclitaxel in patients with advanced solid tumors ( NCI9782 )

Published:2022-04-08 Issue:21 Volume:11 Page:3969-3981
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Medicine

Author:

Leal Ticiana A.¹,Sharifi Marina N.²^ORCID,Chan Nancy³,Wesolowski Robert⁴,Turk Anita A.⁵,Bruce Justine Y.²,O'Regan Ruth M.⁶^ORCID,Eickhoff Jens⁷,Barroilhet Lisa M.⁸,Malhotra Jyoti³,Mehnert Janice⁹,Girda Eugenia³,Wiley Elizabeth⁴,Schmitz Natalie¹⁰,Andrews Shannon²,Liu Glenn²,Wisinski Kari B.²

Affiliation:

1. Winship Cancer Institute Emory University Georgia

2. University of Wisconsin Carbone Cancer Center Madison Wisconsin USA

3. Rutgers Cancer Institute of New Jersey New Brunswick New Jersey USA

4. Ohio State University Comprehensive Cancer Center Columbus Ohio USA

5. Indiana University Simon Comprehensive Cancer Center Indianapolis Indiana USA

6. Department of Medicine University of Rochester Rochester New York USA

7. Department of Biostatistics University of Wisconsin School of Medicine and Public Health Madison Wisconsin USA

8. Department of Obstetrics and Gynecology University of Wisconsin School of Medicine and Public Health Madison Wisconsin USA

9. Perlmutter Cancer Center New York University Grossman School of Medicine New York New York City USA

10. School of Pharmacy University of Wisconsin Madison Wisconsin USA

Funder

National Cancer Institute

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.4724

Reference57 articles.

1. Poly(ADP-ribose) polymerase enzymes and the maintenance of genome integrity

2. The multifaceted roles of PARP1 in DNA repair and chromatin remodelling

3. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

4. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

5. Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An 19F NMR fragment-based approach for the discovery and development of BRCA2-RAD51 inhibitors to pursuit synthetic lethality in combination with PARP inhibition in pancreatic cancer;European Journal of Medicinal Chemistry;2024-02

2. In vitro antitumor activity of carboplatin and analogues;Journal of Coordination Chemistry;2023-11-21

3. Discovery of novel 2,3,4,5-tetrahydrospiro[benzo[c]azepine-1,1’-cyclohexan]-5-ol derivatives as PARP-1 inhibitors;BMC Chemistry;2023-10-27

4. DNA repair biomarkers to guide usage of combined PARP inhibitors and chemotherapy: A meta-analysis and systematic review;Pharmacological Research;2023-10

5. Identification and evaluation of a novel PARP1 inhibitor for the treatment of triple-negative breast cancer;Chemico-Biological Interactions;2023-09